TransCode Therapeutics adjourns special meeting; only 29.94% of shares voted, below quorum

Transcode Therapeutics, Inc.

Special meeting held Feb 4, 2025 lacked quorum (needs one-third of outstanding shares); only 29.94% voted.
Meeting reconvenes Feb 25, 2025 at 9:30 a.m. ET virtually; record date remains Dec 17, 2024.
Proposals include approval of warrant share issuance (Series C and D) and an adjournment proposal.
Company continues soliciting votes; stockholders can vote by mail, internet, phone, or at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.